This time last year we told you about findings from a Phase III trial investigating a medication for psychosis in Parkinson’s disease (PD) patients. Psychosis, a condition associated with a loss of contact with reality, can be a problem for many living with PD and is more common among older Parkinson's patients and those who experience cognitive impairment.

The study, from ACADIA Pharmaceuticals, found that the drug pimavanserin was safe and effective against psychosis.

This month ACADIA published on the study in the Lancet journal.

“Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist,” wrote the authors.